Our findings seem to corroborate this view—among the 38 adults with PNH who received anti-complement therapy with C5/3i, about one-third required successive transfusions within 18 months after anti-complement therapy initiation and 30.8% after 24 months, suggesting the need for other treatment options that act on the early phases of complement activation and are able to control C3-mediated extravascular hemolysis [37]. The gene discussed is C5; the disease is paroxysmal nocturnal hemoglobinuria.